Splicing factor TRA2B enhances synthesis of androgen receptor variant AR-V7 in prostate cancer cells - PubMed
10 hours ago
- #Prostate Cancer
- #AR-V7
- #Splicing Factor
- Prostate cancer progression to castrate-resistant prostate cancer (CRPC) is driven by constitutively active androgen receptor splice variants (AR-Vs) like AR-V7.
- Splicing factor TRA2B enhances the synthesis of AR-V7, promoting its production over full-length androgen receptor isoforms.
- TRA2B expression correlates with AR-V7 transcript levels in CRPC, and inhibiting TRA2-mediated splicing reduces prostate cancer cell growth.
- Targeting TRA2B may offer new therapeutic avenues for treating advanced prostate cancer resistant to current androgen receptor-targeting therapies.